Go Pro
→ Do this before December or regret it (From Porter & Company) (Ad)tc pixel Free CMPX Stock Alerts

Compass Therapeutics (CMPX) Competitors

Compass Therapeutics logo
$2.02 -0.03 (-1.46%)
Closing price 04:00 PM Eastern
Extended Trading
$2.05 +0.03 (+1.53%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CMPX vs. MPLT, IMCR, SEPN, HROW, and MRVI

Should you buy Compass Therapeutics stock or one of its competitors? MarketBeat compares Compass Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Compass Therapeutics include Maplight Therapeutics (MPLT), Immunocore (IMCR), Septerna (SEPN), Harrow (HROW), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Compass Therapeutics compare to Maplight Therapeutics?

Compass Therapeutics (NASDAQ:CMPX) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Compass Therapeutics currently has a consensus price target of $12.25, suggesting a potential upside of 506.44%. Maplight Therapeutics has a consensus price target of $39.73, suggesting a potential upside of 10.38%. Given Compass Therapeutics' higher probable upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Maplight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87
Maplight Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
5 Strong Buy rating(s)
3.12

68.4% of Compass Therapeutics shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by company insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Compass Therapeutics has higher revenue and earnings than Maplight Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass Therapeutics$850K427.98-$66.49M-$0.41N/A
Maplight TherapeuticsN/AN/A-$161.15M-$40.99N/A

Maplight Therapeutics' return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -39.75% -35.29%
Maplight Therapeutics N/A N/A N/A

In the previous week, Compass Therapeutics had 1 more articles in the media than Maplight Therapeutics. MarketBeat recorded 2 mentions for Compass Therapeutics and 1 mentions for Maplight Therapeutics. Compass Therapeutics' average media sentiment score of 0.59 beat Maplight Therapeutics' score of 0.34 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maplight Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Compass Therapeutics beats Maplight Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Compass Therapeutics compare to Immunocore?

Immunocore (NASDAQ:IMCR) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Immunocore has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 10.1% of Immunocore shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Compass Therapeutics has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. Immunocore's return on equity of -7.07% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immunocore-6.68% -7.07% -2.55%
Compass Therapeutics N/A -39.75%-35.29%

Immunocore has higher revenue and earnings than Compass Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immunocore$400.02M4.33-$35.51M-$0.55N/A
Compass Therapeutics$850K427.98-$66.49M-$0.41N/A

Immunocore presently has a consensus price target of $56.71, suggesting a potential upside of 66.56%. Compass Therapeutics has a consensus price target of $12.25, suggesting a potential upside of 506.44%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Immunocore.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunocore
1 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.40
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87

In the previous week, Immunocore and Immunocore both had 2 articles in the media. Compass Therapeutics' average media sentiment score of 0.59 beat Immunocore's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunocore
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Compass Therapeutics beats Immunocore on 11 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Septerna?

Septerna (NASDAQ:SEPN) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

In the previous week, Septerna and Septerna both had 2 articles in the media. Compass Therapeutics' average media sentiment score of 0.59 beat Septerna's score of 0.37 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Septerna presently has a consensus target price of $45.89, indicating a potential upside of 42.47%. Compass Therapeutics has a consensus target price of $12.25, indicating a potential upside of 506.44%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87

Septerna has higher revenue and earnings than Compass Therapeutics. Septerna is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$45.95M31.60-$48.88M-$0.81N/A
Compass Therapeutics$850K427.98-$66.49M-$0.41N/A

68.4% of Compass Therapeutics shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Compass Therapeutics has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-49.88% -12.72% -8.87%
Compass Therapeutics N/A -39.75%-35.29%

Summary

Compass Therapeutics beats Septerna on 10 of the 15 factors compared between the two stocks.

How does Compass Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Harrow has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Harrow-5.57% 19.59% 2.26%
Compass Therapeutics N/A -39.75%-35.29%

In the previous week, Harrow had 5 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Harrow and 2 mentions for Compass Therapeutics. Harrow's average media sentiment score of 0.65 beat Compass Therapeutics' score of 0.59 indicating that Harrow is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Harrow
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Harrow has higher revenue and earnings than Compass Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harrow$272.30M6.09-$5.14M-$0.41N/A
Compass Therapeutics$850K427.98-$66.49M-$0.41N/A

72.8% of Harrow shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Harrow currently has a consensus price target of $69.43, indicating a potential upside of 56.19%. Compass Therapeutics has a consensus price target of $12.25, indicating a potential upside of 506.44%. Given Compass Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Harrow.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harrow
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87

Summary

Compass Therapeutics beats Harrow on 9 of the 16 factors compared between the two stocks.

How does Compass Therapeutics compare to Maravai LifeSciences?

Compass Therapeutics (NASDAQ:CMPX) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Compass Therapeutics presently has a consensus target price of $12.25, indicating a potential upside of 506.44%. Maravai LifeSciences has a consensus target price of $5.50, indicating a potential downside of 21.32%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Compass Therapeutics is more favorable than Maravai LifeSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.87
Maravai LifeSciences
2 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Maravai LifeSciences had 4 more articles in the media than Compass Therapeutics. MarketBeat recorded 6 mentions for Maravai LifeSciences and 2 mentions for Compass Therapeutics. Maravai LifeSciences' average media sentiment score of 0.63 beat Compass Therapeutics' score of 0.59 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Maravai LifeSciences
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Compass Therapeutics has higher earnings, but lower revenue than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Compass Therapeutics$850K427.98-$66.49M-$0.41N/A
Maravai LifeSciences$185.74M9.72-$130.77M-$0.71N/A

Compass Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Compass Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. Maravai LifeSciences' return on equity of -17.87% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Compass TherapeuticsN/A -39.75% -35.29%
Maravai LifeSciences -51.07%-17.87%-9.08%

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 18.7% of Compass Therapeutics shares are held by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Compass Therapeutics beats Maravai LifeSciences on 12 of the 17 factors compared between the two stocks.

Get Compass Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

Export
MetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$369.18M$3.69B$6.90B$12.28B
Dividend YieldN/A2.16%2.67%9.39%
P/E Ratio-4.9320.4927.1023.94
Price / Sales427.98300.39517.5191.92
Price / CashN/A60.3126.6847.25
Price / Book1.827.9210.666.14
Net Income-$66.49M$23.81M$3.60B$331.74M
7 Day Performance-10.62%-1.27%-1.51%-1.72%
1 Month PerformanceN/A2.56%1.11%-1.44%
1 Year Performance-32.67%42.49%23.77%16.97%

Compass Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMPX
Compass Therapeutics
2.5502 of 5 stars		$2.02
-1.5%		$12.25
+506.4%		-31.7%$369.18M$850KN/A20
MPLT
Maplight Therapeutics
1.6512 of 5 stars		$36.57
-7.0%		$39.10
+6.9%		N/A$1.68BN/AN/A109
IMCR
Immunocore
2.5221 of 5 stars		$32.49
+1.7%		$56.71
+74.6%		-3.7%$1.63B$400.02MN/A320
SEPN
Septerna
2.169 of 5 stars		$34.36
-4.4%		$45.89
+33.6%		+166.1%$1.62B$45.95MN/AN/A
HROW
Harrow
4.3292 of 5 stars		$41.81
-1.6%		$69.43
+66.1%		+30.0%$1.58B$272.30MN/A180

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMPX) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Sam Altman backs small company that could save U.S. power grid
A small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...
Altimetry | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Trump’s emergency dollar reset
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
It’s one of Trump’s biggest holdings. Do you own it?
President Trump holds up to $5 million in shares of an AI company that just landed a nearly $10 billion Pentag...
InvestorPlace | Sponsoredtc pixel